(Q44912086)

7 December 2017

title

Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer (English)

1 reference

7 December 2017

main subject

phase II clinical trial

0 references

phase I clinical trial

0 references

1 reference

1 reference

8

Berchuck A

1 reference

7 December 2017

Alvarez Secord A

1

1 reference

7 December 2017

Jones EL

2

1 reference

7 December 2017

Hahn CA

3

1 reference

7 December 2017

Petros WP

4

1 reference

7 December 2017

Yu D

5

1 reference

7 December 2017

Havrilesky LJ

6

1 reference

7 December 2017

Soper JT

7

1 reference

7 December 2017

Spasojevic I

9

1 reference

7 December 2017

Clarke-Pearson DL

10

1 reference

7 December 2017

Prosnitz LR

11

1 reference

7 December 2017

Dewhirst MW

12

1 reference

7 December 2017

publication date

1 June 2005

1 reference

International Journal of Hyperthermia

7 December 2017

published in

1 reference

7 December 2017

volume

21

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

333-347

1 reference

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Hyperthermia and liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Role of tumour markers in monitoring epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Antibody-conjugated magnetoliposomes for targeting cancer cells and their application in hyperthermia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02656730500110155

10.1080/02656730500110155

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference